In cardiomyopathic hamsters, selective ET(A) antagonism preserves myocardial structure, whereas ET(B) antagonism exacerbates cardiomyocyte degeneration despite improving LV function.
No immediate clinical implications for ET blockade; leaves open ET(A) selectivity for future cardiomyopathy trials.
Selective ET(A) antagonist, but not ET(B) antagonist, reduced the ET-1 content as well as the NADPH diaphorase activity, and preserved the fine structure of LV myocardium in cardiomyopathic hamsters. Long-term blockade of ET(B) receptor might worsen the degeneration of cardiomyocytes through the ET-1/ET(A) system even if LV function could be improved.
No takes yet. Share an insight, caveat, or question.
NISHIDA et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: